Comparative Pharmacology
Head-to-head clinical analysis: PROMAPAR versus PROMAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMAPAR versus PROMAZINE HYDROCHLORIDE.
PROMAPAR vs PROMAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PROMAPAR is a brand name for tramadol, a centrally acting analgesic that binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake, modulating pain perception.
Promazine hydrochloride is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, as well as histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors. It also has moderate serotonin and weak serotonin-dopamine antagonist effects.
5 mg orally twice daily, titrated up to maximum 60 mg/day in divided doses.
25-50 mg intramuscularly every 4-6 hours as needed. Maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-15 hours in moderate-to-severe renal impairment.
Terminal elimination half-life: 12-18 hours; in elderly or hepatic impairment may extend to 30 hours
Primarily renal (70-80% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for approximately 20%.
Primarily renal (approx. 70-80% as metabolites, <1% unchanged); minor biliary/fecal (approx. 15-20%)
Category C
Category C
Antipsychotic
Antipsychotic